• Haemonetics Corporation recently reported clinical study results showing that its VASCADE MVP XL vascular closure system delivered superior performance and maintained a consistent safety profile versus the original VASCADE MVP device in large-bore venous access procedures.
• The study, coming soon after expanded FDA labeling that makes VASCADE MVP XL the only clinically proven extravascular option for venous sheaths up to 17F outer diameter, highlights how product differentiation in advanced electrophysiology procedures could reshape the company’s competitive position in interventional technologies.
• We’ll now examine how VASCADE MVP XL’s expanded FDA labeling for larger-bore venous sheaths may influence Haemonetics’ broader investment narrative and outlook.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Haemonetics Investment Narrative Recap

To own Haemonetics, you need to believe its core plasma, hospital, and interventional technologies can remain relevant while management broadens growth beyond a few U.S. concentrated products. The VASCADE MVP XL data and label expansion modestly support the near term catalyst of improving Interventional Technologies performance, but do not remove the key risk that VASCADE underperformance or competitive pressure could still weigh on growth and margins.

Among recent announcements, the March 2026 FDA label expansion for VASCADE MVP XL ties most directly to this study. By formally extending use to larger venous sheaths used in advanced electrophysiology procedures, the labeling supports Haemonetics’ effort to deepen its footprint in higher value interventional cases, a potential offset to plasma cyclicality but still exposed to execution and competition risks if adoption lags or rivals respond aggressively.

Yet, against this encouraging clinical story, investors should also be aware that rising lower cost competition in vascular closure could...

Haemonetics' narrative projects $1.5 billion revenue and $247.6 million earnings by 2029. This requires 5.3% yearly revenue growth and about a $72.2 million earnings increase from $175.4 million today.

Uncover how Haemonetics' forecasts yield a $86.90 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue of about US$1.6 billion and earnings near US$297 million by 2028, so this new VASCADE MVP XL data could either strengthen that bullish view or prompt revisions, especially if you worry about integration costs and margin pressure from product concentration and competition.

Explore 2 other fair value estimates on Haemonetics - why the stock might be worth as much as 50% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Haemonetics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Haemonetics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Haemonetics' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.